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ABSTRACT 
Escherichia coli K1 (E. coli K1) meningitis continues to be a major threat to neonatal health.  
Previous studies demonstrated that outer membrane protein A (OmpA) of E. coli K1 interacts 
with Ecgp96 in the blood-brain barrier to enter the central nervous system.  Here we show that 
OmpA-Ecgp96 interaction downregulates the peroxisome proliferator-activated receptor-gamma 
(PPAR-γ) and glucose transporter-1 (GLUT-1) levels in human brain microvascular endothelial 
cells (HBMECs) causing disruption of barrier integrity and inhibition of glucose uptake.  The 
suppression of PPAR-γ and GLUT-1 by the bacteria in the brain microvessels of newborn mice 
causes extensive pathophysiology due to IL-6 production.  Pre-treatment with partial or selective 
PPAR-γ agonists ameliorate the pathological outcomes of infection by suppressing IL-6 
production in the brain.  Thus, inhibition of PPAR-γ and GLUT-1 by E. coli K1 is a novel 
pathogenic mechanism in meningitis, and pharmacological upregulation of PPAR-γ and GLUT-1 
levels may provide novel therapeutic avenues. 
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Bacterial meningitis is a serious condition that affects the central nervous system.  Neonatal and 
childhood meningitis in particular result in long-term neurological sequelae in about 50% of the 
survivors [1].  Despite the advent of vaccines and effective antibiotic treatment, there is a recent 
emergence of clonal variants and antibiotic resistance [2].  One of the central yet incompletely 
understood dogmas of bacterial meningitis is the reduced glucose levels in the cereb ospinal 
fluid (CSF) of patients.  The CSF glucose levels are typically correlated to serum glucose levels 
since glucose can be transported across the blood-brain barrier (BBB).  A recent clinical study 
with 3805 normal volunteers with a median age of 2.2 months showed that increased serum 
glucose levels correlated with increased CSF glucose levels.  Therefore, the BBB is the focal 
point for glucose transport from the blood to the CSF.  During bacterial meningitis, the 
requirement of glucose as a fuel by infiltrating immune cells in response to infection is 
considered a reason for the reduced glucose levels [3, 4].  However, the possibility of whether 
bacterial pathogens that cause meningitis can manipulate glucose concentrations in the brain has 
not been explored before. 
 
Escherichia coli K1 (E. coli K1) is the second leading cause of neonatal meningitis, and it uses 
distinct cellular mechanisms to cross the BBB for disease progression [5].  There is a re-
emergence of this pathogen with atypical pathogenic mechanisms [6, 7].  Therefore, it is 
imperative that our understanding of this pathogen is abreast with its ever-changing virulence 
strategies.  We unequivocally established that the outer membrane protein A (OmpA) of E. coli 
K1 binds endothelial cell glycoprotein 96 (Ecgp96) in both human brain microvascular 
endothelial cells (HBMECs), an in vitro model of the BBB, and in a newborn mouse model of 
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meningitis.  This interaction is critical for E. coli K1 to cross the BBB and establish infection [8-
10].  Ecgp96 belongs to the glucose-regulated protein 94 (Grp94) family of heat shock proteins, 
and therefore its expression is typically induced by lack of glucose or glucose starvation [11].  
Our studies also demonstrated the existence of a feedback loop between Ecgp96/TLR2 (Toll-like 
Receptor-2)/AT1R (Angiotensin II Receptor I) protein complex in the membranes of HBMECs 
and intracellular nitric oxide (NO) during the invasion process [12-14]. 
 
The brain is a glucose-dependent organ since fatty acids cannot cross the BBB [15].  The 
peroxisome proliferator-activating receptor (PPAR) superfamily of nuclear receptors plays a vital 
role in cellular glucose uptake by promoting translocation of glucose transporter-1 (GLUT-1) to 
the membrane and facilitating glucose uptake into the brain from blood vessels [16-18].  
Modulation of PPAR-γ and GLUT-1 expression is critical in neurodegenerative disorders [19-
24].  Interestingly, the AT1R antagonist Telmisartan (TS), which effectively blocked E. coli K1 
invasion in vitro and in vivo, also acts as a partial agonist for PPAR-γ activation [14, 25].  
Therefore, we speculated that the initial OmpA binding to Ecgp96 triggers a glucose-deficient 
environment which induces more Ecgp96 expression for bacterial binding and invasion.  In this 
study, we sought to examine the roles of PPAR-γ and GLUT-1 in E. coli K1 invasion of 
HBMECs and the onset of meningitis in newborn mice. 
 
METHODS 
Strains and reagents.  The prototype E. coli K1 strain (O18:K1:H7) and its ompA deletion 
mutant were described previously [26].  The list of antibodies and chemicals used in this study 
are described in detail in the supplementary information. 
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Cell culture and infection assays.  HBMEC cultures and infection protocols were performed as 
before [27].  HBMECs were pre-treated with the respective compounds for 1 h before infection.  
For protein overexpression, HBMECs were transfected with the respective plasmids and invasion 
assays were performed 24 h post-transfection. 
 
Animal studies, immunostaining, and cytokine ELISA.  Animal experiments were performed 
as described previously [26].  Protocols were approved by the Institutional Animal Care and Use 
Committee of Children's Hospital of Los Angeles (Protocol #59-14).  For treatment studies, the 
pups were treated with Telmisartan (TS) or Rosiglitazone (RG) 6 h before infection, during 
infection, and 18 h post-infection.  Details are provided in the supplementary information.  
Cytokine ELISA was performed as per the manufacturer’s protocol.  Hematoxylin and Eosin 
(H&E), immunofluorescence, and brain microvessel staining were executed as reported before 
[14, 24, 26]. 
 
Other methods.  Western blotting using HBMEC lysates, flow cytometry and measurement of 
trans-endothelial electrical resistance (TEER) were performed as described earlier [14].  Glucose 
measurement assays were performed as described earlier [28]. 
 
RESULTS 
E. coli K1 suppresses PPAR-γ and GLUT-1 during the invasion of HBMECs.  To examine if 
PPAR-γ and GLUT-1 play a role in E. coli K1 entry of HBMECs, invasion assays were 
performed in the presence of TS (partial PPAR-γ agonist/anti-hypertensive drug), RG (selective 
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
6 
PPAR-γ agonist/anti-diabetic drug), GW1929 (selective PPAR-γ agonist), and GW9662 (PPAR-
γ antagonist).  The IC50 concentrations were determined using dose-dependent studies prior to 
these experiments (data not shown).  Results revealed that pre-treatment of HBMECs with TS, 
RG, and GW1929 blocked E. coli K1 invasion while pre-treatment with PPAR-γ antagonist 
GW9662 did not have any effect on invasion (Fig. 1A).  Western blot analysis of E. coli K1-
infected HBMEC lysates showed that PPAR-γ expression was suppressed until 30 min, and 
recovered by 90 min post-infection (Fig. 1B).  The expression of GLUT-1 was also significantly 
suppressed in E. coli K1 infected cells as shown by immunoblotting of the infected HBMEC 
lysates.  As previously demonstrated, the expression of Ecgp96, the receptor for E. coli K1 
OmpA, increased with infection.  The expression of AT1R, previously established to be 
important in the invasion process, did not change with infection.  This observation was also 
consistent with our previous findings that total AT1R levels in HBMECs do not change with E. 
coli K1 invasion, but AT1R association with Ecgp96 increases during the invasion process [14].  
No such changes were observed in HBMECs infected with OmpA- E. coli K1. 
 
TS or RG pre-treatment did not significantly alter Ecgp96 or AT1R expression after E. coli K1 
infection of HBMEC compared to E. coli K1 alone infected cells.  In contrast, pre-treatment with 
TS or RG inhibited E. coli K1-mediated suppression of PPAR-γ and GLUT-1, suggesting that 
suppression of these two molecules plays a role in the invasion of E. coli K1 in HBMECs.  To 
rule out the possible involvement of other PPAR isoforms, we performed invasion assays on 
HBMECs pre-treated with PPAR-α agonist CP 775146 and PPAR-β agonist L-165,041.  As 
shown in Figure 1C, both the agonists had no effect on the invasion process.  Furthermore, to 
determine if PPAR-α and PPAR-β expression is affected in E. coli K1 infected HBMECs, 
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Western blots were performed using total cell lysates.  Both the isoforms were expressed in 
detectable amounts in the lysates, but the infection process did not alter their levels (Fig. 1D).  
Additionally, the lysates were also examined for the expression of GLUT-3 and GLUT-4 since 
both these transporters have been identified at basal levels in the BBB of both humans and 
rodents [15, 29].  Consistent with this observation, basal levels of GLUT-3 and GLUT-4 were 
detected in HBMEC lysates, but their levels remained fairly unchanged during the invasion.  
These results confirm that E. coli K1 invasion of HBMECs suppresses the expression of PPAR-γ 
and GLUT-1.  The effect of GLUT-1 agonists on E. coli K1 invasion could not be tested due to 
lack of commercially available compounds that exclusively upregulate GLUT-1.  To circumvent 
this issue, we performed invasion studies in HBMECs overexpressing PPAR-γ and GLUT-1. 
 
Overexpression of recombinant PPAR-γ or GLUT-1 blocks E. coli K1 invasion of 
HBMECs.  To confirm the role of PPAR-γ and GLUT-1 in E. coli K1 entry of HBMECs, 
plasmids overexpressing full-length PPAR-γ (FL-PPAR-γ) or GLUT-1 (FL-GLUT-1) were 
transiently transfected in HBMECs and invasion assays were performed as described above.  
HBMECs overexpressing full-length GLUT-4 (FL-GLUT-4) were used as a control.  Since 
GLUT-4 mediated glucose uptake is strictly insulin-dependent, it was expected to play no role in 
glucose uptake in infected HBMECs [15].  E. coli K1 invasion was reduced by >50% in 
HBMECs overexpressing FL-PPAR-γ or FL-GLUT-1, while its invasion of HBMECs 
overexpressing FL-GLUT-4 was comparable with untransfected or transfection reagent alone-
treated HBMECs (Fig. 2A).  The overexpression of these proteins in transfected HBMECs were 
also comparable as verified by flow cytometry (Fig. 2B).  Western blot analyses of lysates from 
transfected HBMECs infected with E. coli K1 showed that the expressions of Ecgp96, AT1R, 
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PPAR-γ, and GLUT-1 were similar to those observed with RG pre-treated/E. coli K1-infected 
HBMECs (Fig. 2C).  These observations confirm that suppression of PPAR-γ and GLUT-1 
levels either by RG pre-treatment or with plasmid-mediated overexpression blocks E. coli K1 
invasion. 
 
E. coli K1 suppresses glucose uptake and induces tight junction disruption in HBMECs 
during the invasion.  To demonstrate the direct role of glucose uptake in HBMECs in 
preventing E. coli K1 invasion, a colorimetric assay to quantify 2-deoxyglucose (2-DG) uptake 
was performed. [28].  E. coli K1 suppressed glucose uptake in HBMECs in comparison to 
uninfected control HBMECs.  Treatment with TS or RG before infection with E. coli K1 rescued 
the glucose uptake levels to those seen in uninfected controls (Fig. 3A).  In contrast, 
overexpression of FL-PPAR-γ or FL-GLUT-1 enhanced glucose levels despite infection with E. 
coli K1 when compared to those levels in HBMECs infected with the bacteria alone (Fig. 3B).  
These observations indicate a direct correlation between PPAR-γ, GLUT-1, and glucose uptake, 
and confirm our hypothesis that E. coli K1 suppresses glucose uptake mechanisms mediated by 
PPAR-γ and GLUT-1 in HBMECs during infection. 
 
The expression of PPAR-γ and GLUT-1 is vital for the barrier integrity of the BBB [24, 30].  We 
previously reported that disruption of tight junction (TJ) and adherens junction (AJ) integrity 
plays a key role in E. coli K1 translocation across the HBMEC monolayer [27, 31].  Moreover, 
pre-treatment of HBMECs with TS completely inhibited E. coli K1-mediated barrier disruption 
[14].  To determine whether the selective PPAR-γ agonist RG or overexpression of PPAR-γ and 
GLUT-1 plasmids also prevented junction disruption, trans-endothelial electrical resistance 
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(TEER) was measured in E. coli K1-infected HBMECs. Similar to TS, RG pre-treatment or 
plasmid overexpression also inhibited the ability of E. coli K1 to disrupt barrier integrity (Fig. 
3C-D).  Therefore, E. coli K1 signals for barrier disruption in HBMECs through the 
Ecgp96/AT1R/TLR2 complex, and this process involves suppression of PPAR-γ and/or GLUT-
1. 
 
Specific activation of PPAR-γ prevents the onset of meningitis in newborn mice.  Our results 
show that PPAR-γ and GLUT-1 may play a role in modulating glucose uptake in HBMECs, an 
in vitro model of BBB during E. coli K1 invasion.  To establish the exclusive role of PPAR-γ in 
a newborn mouse model of E. coli K1 meningitis, infection experiments with E. coli K1 were 
performed in 2-day-old mouse pups in the presence or absence of RG pre-treatment as described 
in methods.  TS-S (TS-sulfate, a soluble ester of TS) pre-treatment was used as a control based 
on our earlier observations that TS-S prevented the onset of meningitis in vivo [14].  Newborn 
mice infected with E. coli K1 were positive for bacteria in the blood, brain, and CSF by 24 h 
post-infection.  In contrast, pups pre-treated with TS or RG before infection were resistant to 
meningitis and survived (Fig. 4A-C).  Hematoxylin and Eosin (H&E) staining of the brain 
sections revealed that cortex, meninges, and hippocampus regions of the infected brains were 
severely affected while brains from uninfected and compound pre-treated pups showed no such 
damage (Fig. 4D). 
 
E. coli K1 alters pro-inflammatory cytokine profiles in the serum and brain of newborn 
pups.  E. coli K1 infection causes brain damage similar to the human disease in infected mouse 
pups as evidenced by pathological damage and neutrophil infiltration [26, 32, 33].  H&E staining 
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revealed severe brain pathology in infected pups due to the excessive neutrophil influx caused by 
pro-inflammatory cytokines.  To identify the pattern of cytokine expression concurrent with 
disease progression, multiplex cytokine ELISA was performed to check for IL-6, IL-1β, TNFα, 
IL-12p70, IFNγ, IL-4, IL-5, and IL-10 expression in serum samples and brain homogenates.  
Results showed that E. coli K1 induces pro-inflammatory IL-6, IL-1β, and TNFα levels in serum 
samples (Fig. 5A-B).  No significant changes in IL-12p70, IFNγ, IL-4, IL-5, and IL-10 
expression were detected.  However, only IL-6 was significantly upregulated in the brains of 
infected pups.  Pre-treatment with TS or RG inhibited the upregulation of IL-6, IL-1β, and TNFα 
levels in the serum.  These results show that E. coli K1 induces a typical “cytokine storm” which 
primarily involves IL-6 to potentially cause inflammation-mediated damage in the brains of 
infected mice.  Interestingly, TS or RG failed to induce a compensatory mechanism of anti-
inflammatory cytokine activation (IL-4, IL-5, and IL-10).  Rather, the compounds directly 
suppressed E. coli K1-mediated IL-6 upregulation, which may play a role in the eventual 
clearance of the bacteria from the systemic circulation, thus preventing the onset of meningitis. 
 
E. coli K1 infection causes reciprocal regulation of Ecgp96/AT1R and PPAR-γ/GLUT-1 
levels in the brains of mouse pups.  Our in vitro data show that E. coli K1 suppresses the 
expression of PPAR-γ and GLUT-1 in HBMECs.  Therefore, we examined if E. coli K1 
infection also causes suppression of these molecules at the BBB in vivo.  We previously 
demonstrated that the E. coli K1 infection affects cortex, meninges, and hippocampus regions of 
the brain [9, 26].  Moreover, we showed that Ecgp96 levels are upregulated in these regions of 
the brain during E. coli K1 infection [9].  To determine whether elevated Ecgp96 levels lead to a 
concomitant upregulation of AT1R and suppression of PPAR-γ and GLUT-1 levels, we 
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determined the expression of Ecgp96, AT1R, PPAR-γ, and GLUT-1 in the brain sections by 
immunofluorescence.  Consistent with previous observations, Ecgp96 levels were elevated in the 
meninges and hippocampus of infected pups, as were AT1R levels (Fig. 6A-B) [9].  However, 
PPAR-γ and GLUT-1 levels were downregulated in the E. coli K1-infected brains.  In contrast, 
Ecgp96 and AT1R levels were basal, while PPAR-γ and GLUT-1 levels were higher in TS-S and 
RG + E. coli K1 pups than in uninfected pups.  Compound alone-treated pups (no infection) also 
showed elevated levels of PPAR-γ and GLUT-1 (data not shown), implying that upregulation of 
their levels using chemical agonists prevented bacterial translocation across the BBB.  To 
examine the expression of these markers at the BBB, brain microvessels were stained with 
tomato lectin in the brain sections.  Consistent with the patterns above, the expression of Ecgp96 
and AT1R was upregulated in the microvessels of infected tissue while PPAR-γ and GLUT-1 
levels were downregulated (Fig. 6C-D).  An inverse phenomenon was observed in the brain 
microvessels of TS-S and RG + E. coli K1 pups compared to E. coli K1-infected mouse brains.  
The localization of Ecgp96, AT1R, and GLUT-1 to the membrane of the microvessels and 
cytoplasmic expression of PPAR-γ are clearly observed.  These results suggest that E. coli K1 
invasion of brain microvessels downregulates PPAR-γ and GLUT-1 expression to infect deeper 
tissue. 
 
DISCUSSION 
Most E. coli strains that cause meningitis contain K1 capsular polysaccharide, which is shown to 
be necessary for survival in the host [34].  We demonstrated that OmpA is also important for the 
survival of E. coli K1 strains [10].  Mutation in extracellular loops 1 and 2 of OmpA prevented 
meningitis in newborn mice.  These two loops have slight differences in their sequences 
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compared to non-pathogenic E. coli.  Moreover, they interact with the N-glycans of Ecgp96 to 
enter HBMECs [9].  Since Ecgp96 upregulation has been correlated with glucose starvation, we 
analyzed whether alterations of glucose uptake mechanisms mediated by the OmpA-Ecgp96 
interaction play a role in E. coli K1 meningitis. 
 
The promotion of glucose uptake by PPAR-γ and GLUT-1 has been a well-established paradigm 
in the maintenance of brain health. [15, 35-37].  However, the role of PPAR-γ and/or GLUT-1 in 
meningitis has not been explored previously.  The data presented here using in vitro and in vivo 
models clearly indicate a critical role played by these markers in the development of neonatal 
meningitis by E. coli K1.  We also propose an inverse correlation between Ecgp96 and PPAR-γ 
wherein the binding of E. coli K1 OmpA to basal levels of Ecgp96 causes suppression of PPAR-
γ.  This leads to inhibition of glucose uptake due to the downregulation of GLUT-1 expression.  
This glucose-deficient environment leads to a stress response in the BBB, thereby further 
enhancing the expression of Ecgp96 for more bacteria to bind and invade. 
 
Pathogens including Brucella, Listeria, and enteroaggregative E. coli have been recently shown 
to upregulate PPAR-γ [28, 38, 39].  On the contrary, we demonstrated here that E. coli K1 
suppresses PPAR-γ and GLUT-1 levels in the endothelial cells forming the BBB, and 
upregulation of PPAR-γ (using partial and selective PPAR-γ agonists) prevented E. coli K1 
translocation of the BBB to establish infection.  The role of PPAR-γ and GLUT-1 in the 
maintenance of tight junction (TJ) and adherens junction (AJ) integrity is well recognized [40, 
41].  Furthermore, we previously showed that E. coli K1 disrupts AJ during the invasion of the 
BBB [27, 31].  Our current results demonstrated that pharmacological augmentation of PPAR-γ 
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levels using TS or RG prevents AJ disruption, and therefore manipulation of PPAR-γ levels by 
E. coli K1 may be a critical step in the invasion process.  We showed that TS pre-treatment 
inhibited E. coli K1-mediated AJ disruption [14].  Our current data further confirms that TS 
exerts its activity as an inhibitor of bacterial invasion by both AT1R antagonism and PPAR-γ 
upregulation.  Furthermore, this dual activity of TS was helpful in the establishment of a 
previously unknown signaling link between E. coli K1 OmpA and its receptor Ecgp96 (along 
with AT1R and TLR2), PPAR-γ, and endothelial barrier integrity. 
 
Disruption of BBB integrity causes an influx of inflammatory mediators that cause extensive 
tissue damage [42].  E. coli K1 causes brain damage by inducing neuronal apoptosis and 
neutrophil infiltration in the brains of infected mouse pups [26].  However, the specific 
inflammation patterns underlying the observed pathology in either humans or mice are not well 
studied.  Our results clearly show a prominent role of the pro-inflammatory cytokine IL-6 as a 
mediator of brain damage.  Interestingly, IL-6 levels were also elevated in meningitis caused by 
Group B Streptococcus (GBS) and Haemophilus influenzae type B (Hib) [43, 44].  Moreover, 
increased IL-6 production by astrocytes and microglia during brain injury or meningitis leads to 
increased influx of leukocytes into the brain [45, 46].  Therefore, neutrophil infiltration during E. 
coli K1 meningitis may be a result of IL-6 production.  IL-6 upregulation in the brain 
corresponding to the lack of PPAR-γ activity was recently shown in Alzheimer’s disease [47].  In 
agreement, preservation of PPAR-γ activity by pre-treatment with TS or RG effectively inhibited 
E. coli K1-mediated IL-6 production, promoted bacterial clearance, and prevented inflammation-
related pathology.  Another interesting observation here is that though E. coli K1-mediated 
suppression of PPAR-γ and GLUT-1 levels is consistent in vitro and in vivo, E. coli K1 does not 
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induce cellular damage in HBMECs even after 24 h-post infection (unpublished observation).  
Therefore, the extensive tissue damage seen in vivo maybe the result of IL-6 induction due to 
lack of PPAR-γ activity during infection.  However, further studies using IL-6 knockout mice are 
needed to conclusively demonstrate the role of IL-6 in E. coli K1-induced brain damage. 
 
The current study unravels a unique infection strategy employed by E. coli K1 in the 
pathogenesis of neonatal meningitis by manipulating PPAR-γ and GLUT-1 levels.  The 
modulation of these proteins exhibits a causal effect on barrier disruption and inhibition of 
glucose uptake, thereby providing new avenues for therapeutic approaches.  The inhibition of 
glucose uptake at the BBB could be an additional factor contributing to the low glucose levels in 
the CSF during E. coli K1 meningitis.  The clinical diagnosis of meningitis is based on CSF-
positive cultures for E. coli K1.  However, the study involves pre-treatment with PPAR-γ 
agonists before experimentally inducing meningitis.  Therefore, the most credible therapeutic 
strategies would involve the use of antibiotics in conjunction with TS or RG to override 
suppression of glucose uptake by E. coli K1.  Our unpublished observations reveal that 
supplementing antibiotic treatment with TS results in a quicker resolution of brain inflammation 
in pups compared to those treated and rescued with antibiotics alone.  This short-term 
antibiotic/TS treatment does not seem to have lasting sequelae on these animals when they 
eventually reach adulthood.  Clinical studies indeed show that short-term treatment regimens 
(ranging from 3 weeks to 24 weeks) of the anti-hypertensive drug Candesartan (an angiotensin 
receptor blocker similar to TS) in children with hypertension (ages 1 to 18 years) does not cause 
any adverse effects [48].  Since brain inflammation during meningitis causes intracranial 
hypertension, adjunct treatment with TS may also help resolve intracranial hypertension along 
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with suppression of IL-6 levels leading to better brain recovery [49].  It is unclear if the effects of 
TS or RG on PPAR-γ in other cell types contribute to the reduction in blood and brain bacterial 
levels in E. coli K1-infected mice.  Further studies using brain endothelial cell specific PPAR-γ 
knockout mice are needed to validate the role of PPAR-γ in the onset of meningitis.  
Nevertheless, therapeutic intervention with PPAR-γ agonists along with antibiotics may 
eventually evolve into an effective method of preventing morbidity and neurological sequelae in 
meningitis due to E. coli K1 and perhaps other bacterial pathogens. 
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Figure 1.  E. coli K1 suppresses PPAR-γ and GLUT-1 expression during the invasion of 
HBMECs.  (A) Bacterial invasion assays in HBMECs were performed using the following 
concentrations of TS (39 µM), RG (50 µM), GW1929 (50 µM), and GW9662 (33 nM).  Data 
represent relative invasion compared to E. coli K1 in the presence of DMSO taken as 100% and 
are averages of three independent experiments.  Error bars indicate standard deviation.  *p < 0.05 
by Student’s t-test compared to DMSO.  (B) Lysates from HBMECs exposed to bacteria for up 
to 90 min in the presence or absence of compound pre-treatment for 1 h were probed for 
expression of Ecgp96, PPAR-γ, GLUT-1, and AT1R.  β-actin was used as a loading control; C 
indicates uninfected control.  The blots shown are representative of two independent experiments 
with similar results.  (C) Bacterial invasion assays on HBMECs were performed using the 
following concentrations of PPAR-α agonist CP 775146 (24.5 nM) or PPAR-β agonist L-
165,041 (125 nM).  Data represent relative invasion compared to E. coli K1 in the presence of 
DMSO taken as 100% and are averages of three independent experiments.  Error bars indicate 
standard deviation.  (D) Expression levels of PPAR-α, PPAR-β, GLUT-3, and GLUT-4 were 
analyzed from lysates of HBMECs infected with E. coli K1 for various time points as indicated.  
β-actin was used as a loading control; C indicates uninfected control.  The blots shown are 
representative of two independent experiments that exhibited similar results. 
Figure 2.  Overexpression of recombinant PPAR-γ or GLUT-1 blocks E. coli K1 invasion of 
HBMECs.  (A) HBMECs transfected with plasmids expressing full-length (FL)-PPAR-γ, (FL)-
GLUT-1, or (FL)-GLUT-4 were subjected to invasion assays with E. coli K1.  Data represent 
relative invasion compared to E. coli K1 in the presence of Lipofectamine 3000 (Lipo) taken as 
100% and are averages of three independent experiments.  Error bars indicate standard deviation.  
*p < 0.05 by Student’s t-test compared to Lipofectamine 3000 (Lipo).  (B) Flow cytometry 
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analysis of untransfected and plasmid-transfected HBMECs was performed using respective 
antibodies.  Data are representative of two independent experiments with similar results.  (C) 
Lysates from untransfected or plasmid-transfected HBMECs exposed to bacteria for various time 
points as indicated were probed for expression of Ecgp96, PPAR-γ, GLUT-1, and AT1R.  β-actin 
was used as a loading control; C indicates plasmid-transfected/uninfected control.  The blots 
shown are representative of two independent experiments. 
Figure 3.  E. coli K1 suppresses glucose uptake and induces monolayer permeability in 
HBMECs during the invasion.  HBMECs were pre-treated with (A) compounds or (B) 
transfected with plasmids and infected with E. coli K1.  Colorimetric assessment of glucose 
uptake was measured using 2-deoxyglucose as substrate.  In these graphs, the same results 
obtained with uninfected HBMECs (uninfected) and E. coli K1-infected HBMECs (untreated) 
were used in both panels for clarity.  Error bars indicate standard deviation.  #p < 0.05 by 
Student’s t-test compared to uninfected; *p < 0.05 by Student’s t-test compared to Lipofectamine 
3000 (Lipo).  HBMECs were pre-treated with (C) compounds or (D) transfected with plasmids, 
and infected with E. coli K1 for measurement of trans-endothelial electrical resistance (TEER) at 
various time points.  In these graphs, the same results obtained with uninfected HBMECs 
(uninfected) and E. coli K1-infected HBMECs (E. coli K1) were used in both TEER experiments 
for clarity.  Error bars indicate standard deviation.  *p < 0.05 by Student’s t-test compared to E. 
coli K1 from 30 to 120 min only. 
Figure 4.  Activation of PPAR-γ prevents the onset of meningitis in newborn mice.  Two-
day-old mice were infected with E. coli K1 via an intraperitoneal route as described in the 
Methods.  Blood samples (A) and brains (B) from infected mice were collected 24 h post-
infection and bacterial load was quantified.  Statistical analyses were performed by Student’s t-
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test (p-values indicated); ANOVA verified the significant differences in the means.  (C) CSF 
samples were collected and determined for the presence of bacteria as described in the Methods.  
Positive CSF cultures were indicative of meningitis.  (D) Brain sections were stained for 
pathological analysis using Hematoxylin & Eosin staining.  Arrows indicate normal (uninfected, 
TS-S + E. coli K1, RG + E. coli K1) or damaged (E. coli K1) meninges and hippocampi.  Scale 
bar = 100 µm. 
 
Figure 5.  E. coli K1 modulates cytokine profiles in newborn mice.  Serum samples (A) and 
brain homogenates (B) were used for cytokine analysis using ELISA.  Statistical analyses were 
performed by Student’s t-test and ANOVA; *p < 0.05 by Student’s t-test compared to uninfected 
(UN); #p < 0.05 by Student’s t-test compared to E. coli K1-infected samples (E). 
 
Figure 6.  E. coli K1 promotes reciprocal regulation of Ecgp96/AT1R and PPAR-γ/GLUT-1 
levels in the brains of newborn mice.  The brain sections were stained with antibodies to 
Ecgp96, AT1R, PPAR-γ, and GLUT-1 followed by Alexa 647 fluorophore-coupled (red) 
secondary antibodies.  (A) Meninges and (B) hippocampus are shown for each treatment.  DAPI 
(blue) was used to stain the nuclei. Scale bar = 100 µm.  Additionally, the brain sections were 
stained with tomato lectin (green) to visualize microvessels and for (C) Ecgp96, AT1R, (D) 
PPAR-γ, and GLUT-1 (red) expression in the meninges.  DAPI (blue) was used to stain the 
nuclei.  Scale bar = 20 µm. 
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 at California Institute of Technology on A
ugust 1, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
